The present invention is directed to an intraluminal device and method of fixation of an intraluminal device and, in particular, a technique that enhances both fixation and removeability of the device. While the invention is illustrated for use with a bariatric device and/or a metabolic device, it may be applied to other intraluminal devices positioned in a mammalian lumen or hollow organ that is subject to peristalsis, such as an esophageal stent, an anti-reflux device, a nasal gastric tube, an intestinal sleeve, and the like, including devices positioned in the fallopian tubes, vas deferens, and the like.
An intraluminal device and method of providing satiety and/or treating a metabolic disease in a recipient is disclosed in commonly assigned U.S. Pat. Nos. 7,846,174; 8,100,931; 8,372,087; 8,529,431; 8,672,831; 8,801,599; 8,894,670 and 9,055,998 and International Publications Nos. WO2012/044917; WO2012/162114; WO2013/134227 and WO 2015/031077, the disclosures of which are hereby collectively incorporated herein by reference in their entirety. Such devices and methods apply stress to the gastro-intestinal tract in general and in particular to the cardiac portion of the stomach of the recipient to produce satiety in the absence of food and to augment fullness caused by food and/or to treat a metabolic disease. A challenge with such devices and methods is fixation of a portion of the device against a surface of the GI tract, such as the cardiac portion of the stomach in the presence of peristalsis tending to cause distal migration of the device.
While the use of tissue ingrowth patented in the above-identified patents has been found to provide a satisfactory solution for fixation to resist distal migration, aspects of the present invention includes providing short-term fixation of the device until the tissue ingrowth providing long-term fixation is in place. Such short-term fixation is easy to carry out and capable of complete fixation over the days or weeks that it takes for the long-term fixation to occur.
Aspects of the present invention provide techniques for explanation of an intraluminal device having a wall defining first and second wall portions configured to be positioned in a lumen. The first wall portion may be an esophageal portion that is configured to the size and shape of a portion of the esophagus. The second wall portion may be a cardiac portion that is configured to the size and shape of the cardiac portion of the stomach. A connector connecting the esophageal and cardiac portions is positioned against lumen tissue, such as in the gastroesophageal (GE) junctions wherein lumen tissue bridges or encases the connector during deployment of the device. Explanation of the device should not substantially damage the GE junction of the recipient. Aspects of the present invention facilitate such explanation and provide techniques that may beneficially utilize such tissue bridging the connector for long-term fixation of an intraluminal device.
An intraluminal device adapted to be positioned in a lumen, according to an aspect of the invention, includes a wall having a first wall portion configured to the size and shape of a first portion of the lumen and a second wall portion configured to the size and shape of a second portion of the lumen. A connector is connected with the first wall portion with the second wall portion. The connector is configured to be positioned against the lumen and wherein the connector is separably connected with one or both of the first and second wall portions. This allows the device to be explanted by disconnecting the connector and axially withdrawing the connector from tissue that encases the connector without substantial damage to the tissue.
The wall portions may be joined with the connector prior to deployment in the lumen. The connector may include at least one filament that is coated with a bio-compatible material that extends around the at least one filament from one of the wall portions to the other of the wall portions. A removable attachment may connect the connector with at least one of the wall portions and wherein the connector is separable by removing the removable attachment. The removable attachment may include a severable filament.
The device may include a fixation system that is configured to resist distal migration of the wall in the lumen. The fixation system may include the connector having a configuration to facilitate tissue of the lumen growing around the connector. The fixation system may include a tissue penetrating fastener configured to engage the connector with tissue of the lumen. The connector may include at least one elongated member including irregular portions thereof.
The fixation system may include a long-term fixation system including a characteristic of the wall that is configured to facilitate tissue adhesion to the wall and a temporary fixation system that at least initially resists distal migration of the wall, wherein the temporary fixation system includes a tissue penetrating fastener. The temporary fixation system may include a looped filament extending from that at least one of the wall portions and is configured to be captured with the fastener. The looped filament may be at least partially elastic and may be at least partially bioabsorbable.
The intraluminal device may be an esophageal stent, an anti-reflux device, a nasal gastric tube, an intestinal sleeve, a bariatric device or a metabolic disease treatment device.
An intraluminal device adapted to be positioned at the gastro-esophageal (GE) region of a recipient, according to an aspect of the invention, includes a wall defining an esophageal portion that is configured to the size and shape of a portion of the esophagus and a cardiac portion that is configured to the size and shape of the cardiac portion of the stomach. A connector is connected with said esophageal and cardiac portions and configured to be positioned at the GE junction. The connector is separably connected with the esophageal portion and/or the cardiac portion.
The connector may be separably connected with the wall with a removable attachment. A separable portion of the connector may extend along the wall and the removable attachment may be a severable filament between the separable portion and the wall. The wall may include a structural mesh defining intersections and covered with a biocompatible coating and the separable portion of the connector includes one or more openings defined by the connector that align with one or more intersections of the mesh wherein the severable filament extends between the opening(s) and the intersection(s). A plurality of openings and intersections may be aligned and the severable filament formed as a chain stitch between the openings and intersections.
The wall may include a structural mesh defining intersections and covered with a biocompatible coating with a separable portion of the connector extending over one or more intersections and under one or more intersections. The removable attachment is between the separable portion and the mesh keeping the connector from sliding with respect to the intersections. The removable attachment may be a filament between said distal portion and the mesh. A bead may be provided on the filament to provide access to the filament. The connector may extend over a plurality of intersections and under at least one intersection that is between the plurality of intersections.
The connector may include a filament and a biocompatible coating over the filament. The connector may include a therapeutic agent eluting coating. A therapeutic agent dispensing reservoir may be at a distal portion of the esophageal portion that is adapted to dispense a therapeutic agent to the connector. The device may be a bariatric device used to treat excess body mass or a metabolic device used to treat metabolic disease.
An intraluminal device adapted to be deployed at the gastroesophageal (GE) region of a recipient, according to an aspect of the invention, includes a wall defining a cardiac portion that is configured to the size and shape of the cardiac portion of the stomach, an esophageal portion that is configured to the size and shape of a portion of the esophagus and a connector connected with said esophageal portion and said cardiac portion. A fixation system is configured to resist distal migration of the wall and includes short-term fixation and long-term fixation. The long-term fixation includes a characteristic of the wall that is configured to facilitate tissue ingrowth. The short-term fixation at least temporarily resists distal migration of the wall while tissue grows to the wall as the characteristic. The long-term fixation and short-term fixation are at least partially at the connector.
The characteristic of the wall may include the connector being an elongated filament. The characteristic of the wall may be a tissue ingrowth promotion surface configuration of the connector. The tissue ingrowth promotion surface configuration may face inwardly away from the GE junction.
The short-term fixation may include a tissue penetrating fastener that fixes the device at least partially at the GE junction. The tissue penetrating fastener may face outwardly toward the GE junction. The tissue penetrating fastener may engage the GE junction as a function of deployment of the device at the GE region of the recipient. The tissue penetrating fastener may be applied to tissue at the connector after deployment of the device at the GE region of the recipient. The tissue penetrating fastener may be positioned in part at the esophageal portion. The tissue penetrating fastener positioned in part at the esophageal portion may be configured to penetrate the tissue of the lumen upon deployment of the device. The tissue penetrating fastener may be made at least in part from a bio-absorbable material.
The connector may include a filament and a biocompatible coating over the filament. The connector may include a therapeutic agent eluting coating. A therapeutic agent dispensing reservoir may be at a distal portion of the esophageal portion that is adapted to dispense a therapeutic agent to the connector. The device may be a bariatric device used to treat excess body mass or a metabolic device used to treat metabolic disease.
An intraluminal device adapted to be deployed at the gastroesophageal (GE) region of a recipient, according to an aspect of the invention, includes a wall defining a cardiac portion that is configured to the size and shape of the cardiac portion of the stomach, an esophageal portion that is configured to the size and shape of a portion of the esophagus and a connector connected with said esophageal portion and said cardiac portion. A fixation system is configured to resist distal migration of said wall. The fixation system includes short-term fixation and long-term fixation. The long-term fixation includes a characteristic of the wall that is configured to facilitate tissue ingrowth. The short-term fixation is configured to at least temporarily resist distal migration of the wall while tissue grows to said wall as said characteristic. The short-term fixation includes a tissue penetrating fastener.
The short-term fixation may include a looped filament extending proximally from at least the esophageal portion that is configured to be captured by the tissue penetrating fastener. The looped filament may be made at least in part of an elastic material and/or a bioabsorbable material. An enlarged portion of the looped filament may be provided wherein the fastener penetrates tissue and the enlarged portion. A retainer filament may be provided that is temporarily connected with the looped filament. The retainer filament extends from the esophagus for use with positioning the wall at the GE junction of the recipient. The retainer filament may be removed after deployment of the device.
The tissue penetrating fastener may include a suture. The tissue penetrating fastener may include barbs on the wall and facing the GE region. The barbs engage the tissue of the GE region upon deployment of the device. The barbs may be formed on the wall. The barbs may be formed on a separate fastener attached with the wall or formed on the wall. The fastener may be at least partially made with a bio-absorbable material. A tissue attachment surface may be provided on the tissue penetrating fastener opposite the barbs to attach tissue drawn around the connector. The temporary fixing may provide diminishing resistance of distal migration after long-term fixing of the wall to the GE region has at least partially occurred. The wall characteristic may include tissue ingrowth openings in the wall. A therapeutic drug eluting coating may be provided at the openings in the wall.
The device may be a bariatric device used to treat excess body mass or a metabolic device used to treat metabolic disease.
A method of deployment of an intraluminal device to resist distal migration in a mammalian lumen or hollow organ that is subject to peristalsis, according to an aspect of the invention, wherein the intraluminal device includes spaced apart wall portions connected with a connector. The wall portions are configured to the size and shape of a portion of the lumen or hollow organ and the connector is configured to be positioned against a wall of the lumen or hollow organ. The intraluminal device is positioned in a mammalian lumen or hollow organ that is subject to peristalsis. The device is fixed in the lumen or hollow organ against distal migration, wherein tissue lining the lumen or hollow organ bridges over the connector. The device is explanted after tissue bridges over the connector including separating the connector from one or both of the wall portions and withdrawing the connector axially from the tissue bridging over the connector.
A method of deployment of an intraluminal device at the gastroesophageal (GE) region of the recipient to resist distal migration, the device having a wall defining an esophageal portion that is configured to the size and shape of a portion of the esophagus, a cardiac portion that is configured to the size and shape of the cardiac portion of the stomach and a connector connected with the esophageal and cardiac portions, according to an aspect of the invention, includes positioning the device at the GE region with the esophageal portion in the esophagus, the cardiac portion at the cardiac portion of the stomach and at least a portion of said connector at the gastroesophageal (GE) junction, wherein tissue at the GE junction at least partially encompasses the connector. The device is explanted after tissue has encompassed the connector including separating the connector from the esophageal portion and/or the cardiac portion and withdrawing the connector axially from the tissue encompassing the portion of the connector at the gastroesophageal junction.
A method of deployment of an intraluminal device at the gastroesophageal (GE) region of a recipient to resist distal migration, the device having a wall defining a cardiac portion that is configured to the size and shape of the cardiac portion of the stomach, an esophageal portion that is configured to the size and shape of a portion of the esophagus and a connector connected with the esophageal portion and the cardiac portion, according to an aspect of the invention, includes positioning the device at the GE region with the esophageal portion in the esophagus, the cardiac portion at the cardiac portion of the stomach and at least a portion of said connector at the gastroesophageal (GE) junction. Short-term fixation and long-term fixation of the device positioned at the GE region are provided. The long-term fixation includes a characteristic of the wall that is configured to facilitate tissue ingrowth. The short-term fixation at least temporarily resisting distal migration of said wall while tissue grows to the wall characteristic. The providing of long-term fixation includes positioning the device with a characteristic of the wall that is configured to facilitate tissue ingrowth positioned at the GE junction. The providing of short-term fixation includes temporarily fixing the device at least partially at the GE junction.
A method of deployment of an intraluminal device at the gastroesophageal (GE) region of a recipient, the device having a wall defining a cardiac portion that is configured to the size and shape of the cardiac portion of the stomach, an esophageal portion that is configured to the size and shape of a portion of the esophagus and a connector connected with the esophageal portion and the cardiac portion, according to an aspect of the invention, includes positioning the device at the GE region with the esophageal portion in the esophagus, the cardiac portion at the cardiac portion of the stomach and at least a portion of said connector at the gastroesophageal (GE) junction. Short-term fixation and long-term fixation of the device is positioned at the GE region. The long-term fixation includes a characteristic of said wall that is configured to facilitate tissue ingrowth. The short-term fixation at least temporarily resists distal migration of the wall while tissue grows to said wall characteristic. The long-term fixation is provided including positioning the device with a characteristic of said wall that is configured to facilitate tissue ingrowth positioned against the lumen. The short-term fixation is provided including temporarily fixing the device in the lumen to at least temporarily resist distal migration of the wall while tissue grows to said wall as the characteristic including fixing the device with a tissue penetrating fastener.
These and other objects, advantages, purposes and features of the present invention will become apparent upon review of the following specification in conjunction with the drawings.
Referring now to the drawings and the illustrative embodiment depicted therein, an intraluminal device, such as a bariatric device or a metabolic disease treatment 10, has a wall 12 defining an esophageal portion 14 that is configured to the size and shape of a portion of a mammalian lumen or hollow organ, namely, the esophagus, a cardiac portion 16 that is configured to the size and shape of a separated portion of mammalian lumen or hollow organ, namely, the cardiac portion of the stomach and a connector 18 connecting esophageal portion 14 and cardiac portion 16 (
As can be seen in
Fixation of intraluminal device 10 against distal migration includes a fixation technique 22 that fastens esophageal portion 14 with the esophagus with a fastener such as a tissue penetrating fastener 24. A looped filament 26 extending proximally from esophageal portion 14 is captured with fastener 24 engaging the wall of the esophagus by the fastener. The loops in the looped filament are positively engaged by the fastener so that the esophageal portion 14 is firmly fixed to the esophagus by the fastener. The number of loops can vary from one to many and can be any size or shape as long as they are a closed polygon. In the illustrated embodiment, fastener 24 is an endoscopically deployed clip marketed by Ovesco and described in detail in U.S. Pat. No. 8,721,528 for an ENDOSCOPE CAP, the disclosure of which is hereby incorporated herein by reference. Also, although two loops and penetrating fasteners are illustrated, one or more than two may be used.
Fixation technique 22 is intended to provide at least temporary fixation to maintain device 10 in position at the GE region of the recipient with cardiac portion 16 engaging the cardiac region of the stomach while permanent fixation develops. Looped filament 26 may be at least partially elastic in order to be slightly stretched when fastener 24 is deployed to maintain upward pressure on cardiac portion 16 after deployment. Looped filament 26 may be at least partially bioabsorbable, or resorbable, so that it, along with fastener 24, may fall away after permanent fixation occurs as seen in
A retainer filament 30 may be temporarily connected with the looped filament 26 and extending external the recipient of the device from the esophagus. Retainer filament 30 allows the physician or other healthcare worker the ability to position bariatric device 10 properly at the GE region and to apply tension to looped filament 26 until fastener 24 is applied. As retainer filament 30 is merely looped proximally to looped filament 26, it can be easily retraced by pulling on one side of the loop. Looped filament 26 is connected directly with the mesh 32 that provides a structure to bariatric device 10. This allows the looped filament to apply proximal axial force to mesh which force is then distributed over wall 12 without causing a narrowing of esophageal portion 14 as may occur if the looped filament were to be connected with a removal suture (not shown) that encircles esophageal portion 14 proximally and is used to remove device 10. If a proximal force were to be applied to such removal suture, the diameter of esophageal portion 14 may be reduced upon fixation thus counteracting mucosal capture and/or tissue ingrowth of the wall of the esophageal portion to the esophageal wall. While the application of proximal axial force to such removal suture, or ring, may be a useful action to explant intraluminal device 10, it would not be useful in providing fixation.
Thus, the direct connection of looped filament 26 to mesh 32 allows proximal axial force to be applied to esophageal portion 14 without inducing a radially inward force tending to pull wall 12 away from the esophagus wall. While looped filament 26 is shown in
In an alternative technique illustrated in
Fixation of device 10 against distal migration includes temporary fixing, such as using fixation 22, and long-term fixing from wall characteristics that fixes the wall to the GE region through growth of tissue, such as using tissue ingrowth zones 34 formed in wall 12.
Tissue ingrowth zones 34 are openings in the cover 33 of biocompatible material, such as silicone, over mesh 32, which openings allow tissue to grow over members of the mesh. As shown in
Tissue at or adjacent the GE junction, which includes tissue immediately above and below the sphincter, may bridge over one or both struts 20a, 20b of connector portion 18 at the GE junction as seen in
This could at least theoretically be achieved by physically severing the struts, such as using an argon beam coagulator, or the like. In the illustrated embodiments, such axial displacement of the struts is achieved by making struts 20a and 20b separable from the portion of the device wall 12 defining cardiac portion 16 and by separating the struts from the device wall as seen in
Once free of the cardiac portion 16, struts 20a, 20b may be axial withdrawn, or pulled, proximally through the bridging tissue of the GE junction by axial proximal displacement of esophageal portion 14 in the manner discussed above. Once the struts are withdrawn, the esophageal portion 14 can be retracted proximal, using a removal suture (not shown), or the like. The cardiac portion 16 can be removed from the stomach by drawing it into an overtube inserted in the esophagus or other such method. Once free of esophageal portion 14, struts 20c, 20d may be withdrawn, or pulled, proximally through the bridging tissue of the GE junction by axially distal displacement of cardiac portion 16 into the stomach where it can be removed as discussed above. The esophageal portion 14 can be withdrawn proximally. While the embodiment disclosed in
Struts 20a, 20b, 20c, 20d may be each formed from a single continuous metallic filament 38, such as Nitinol or stainless steel that is twisted from distally to proximally as shown in
In one embodiment, removable attachment 42 includes a separable portion of struts 20a, 20b, 20c, 20d extending along the surface of wall 12 as seen in
As discussed above, cardiac portion 16 will be in the stomach and can be removed transorally. In addition to a separate chain stich 46 for each strut as shown, it is possible to extend the chain stitch to encompass separable portions of both struts (not shown) so that the chain stitch filament need be severed only once to break both struts free of the wall portion. Also, it is possible that tissue bridging may only occur at one of strut pairs 20a, 20b, such as strut 20b or one of strut pairs 20c, 20d positioned against the GE sphincter at the angle of HIS. As such, removable attachment 42 may be provided for only one strut.
In an alternative embodiment, an intraluminal device 110 includes a wall 112 defining an esophageal portion 114 configured to the size and shape of a portion of the esophagus, a cardiac portion 116 configured to the size and shape of a portion of the cardiac portion of the stomach and a connector 118 (
Removeable attachment 142 includes a severable knotted filament 150 at a distal end of each strut secures an end of the separable portion of the strut to the wall as seen in
It should be understood that the tissue bridging over struts 20a, 20b, 20c, 20d, 120a, 120b, 120c, 120d which are elongated filaments that provide a wall characteristic that fixes the wall of the respective struts to the GE region through growth of tissue, can be useful as all or part of long-term fixation of device 10, 110. Such long-term fixation may be enhanced by adding length to similar struts 220a, 220b shown in
Also, short-term and/or long-term fixation using the struts can be enhanced by applying tissue penetrative fasteners in the form of retainers 54 to the bridging mucosa (
Other forms of tissue penetrating fasteners can be used, such as EZ clip or a quick-clip, both available from Olympus. In addition to promotion of tissue bridging over the strut(s) 20a, 20b, 20c, 20d, 120a, 120b, 120c, 120d, the retainers 54, 154 may provide resistance to distal migration of esophageal member 14. This helps to provide tension on the struts, thus ensuring cardiac member 16, 116 is in contact with the cardiac portion of the stomach. Thus, clip 54, 154 may provide both immediate short-term fixation of the bariatric device and promote long-term fixation via fusion of tissue bridging struts 20a, 20b, 20c, 20d, 120a, 120b, 120c, 120d.
An intraluminal device 210 is shown in
An alternative issue penetrating fastener 256 around each strut 220a, 220b includes a series of tissue penetrating barbs 257 that are capable of penetrating mucosa, submucosa, and/or musculara at the GE junction when pressed against the tissue. Penetrating barb 257 may have fishhook, or arrowhead, features to avoid withdrawal of the barbs once inserted. Fastener 256 may be formed around the strut as part of manufacture or may be a separate device as shown in
In addition to the dimensions of each strut providing a wall characteristic that causes tissue to grow around the strut, each fastener 256 may have a wall characteristic 259 facing away from the tissue of the GE junction that enhances long-term fixation of wall 212 to the GE region through promoting growth of tissue around the respective strut. Wall characteristic 259 may be a roughened or fenestrated surface, a surface impregnated with a tissue growth agent, or the like. Wall characteristic 259 may include bars similar to barbs 257 such that application of suction to the esophagus of the recipient tends to draw the tissue of the GE junction around the wall characteristic 259 where it is ensnared by the barbs of wall characteristic 259 to further enhance short-term fixation. Fastener 256 may be made in whole or in part from a bioabsorbable material to resorb after tissue grows around the strut to provide long-term fixation of device 210. The resorption of the fastener 256 avoids fastener 256 from impeding axial withdrawal of the struts for device explantation.
Another tissue penetrating fastener 258 having tissue penetrating barbs 257 may be at a portion of esophageal member 214, such as at its distal rim, in order to provide additional temporary fixing of device 210 at the GE region. Fastener 258 is shown formed or otherwise attached to a distal rim of esophageal portion 214 but could be located at any portion of esophageal portion 214. Fastener 258 only provides temporary fixing of device 210 and therefore does not include a wall characteristic 259 that enhances long-term fixing of wall 212 to the GE region. Fastener 258 is made in whole or in part from bioabsorbable material in order to resorb after long-term fixation is in place to avoid interference with explantation of device 240.
As seen in
An alternative retainer 354 shown in
Thus, it is seen that aspects of the present invention encompass short-term and long-term fixation of an intraluminal device, such as a bariatric device, in a lumen, such as the gastro-esophageal region of the recipient. The long-term fixation uses the body's response to the presence of the device to provide long-term fixation. Short-term fixation, such as one or more tissue penetrating fasteners, provide fixation of the device while long-term fixation develops. Once long-term fixation develops, the short-term fixation may slough off or be absorbed as it is no longer needed. Even multiple different types of long-term fixation may be provided in order to provide optimal fixation at different times after deployment. For an example,
It should be understood that
It may also be possible to eliminate tissue ingrown TI and rely exclusively on mucosal capture MC in order to provide long-term fixation. Such alternative may include using one of the illustrated retainers around one or both struts in order to provide short-term fixation while long-term fixation develops, such as by mucosal capture MC around each of the struts. By providing both short-term and long-term fixation at the struts, the intraluminal device should be simpler to deploy and explant. Deployment may occur by the insertion of a retainer clip at one or both struts or even by a self-deploying retainer that penetrates tissue at the GE junction upon positioning of the device in the lumen of the recipient. With long-term fixation provided at the struts alone, the device can be explanted by separating the separable struts and axially retracting the struts from the GE junction by proximally withdrawing the esophageal member from the esophagus. The cardiac member can then easily be retrieved from the stomach. Because tissue ingrowth is not employed in such embodiment, there is no need to remove tissue from the tissue ingrown zones.
The intraluminal device 10, 110, 210 may be made adjustable in order to adjust or titrate the amount of stress on the cardiac portion of the stomach, such as by using a bladder or bladders on the proximal surface of the cardiac portion using the principles disclosed in International Application Publication No. WO2015/031077, the disclosure of which is hereby incorporated herein by reference in its entirety. Besides providing for adjustability, such bladder(s) may be filed with a fluid made of a lighter-than-air gas, such as helium, hydrogen, or the like, in order to assist in urging the cardiac member against the cardiac portion of the stomach in order to at least partially provide short- or long-term fixation.
While the foregoing description describes several embodiments of the present invention, it will be understood by those skilled in the art that variations and modifications to these embodiments may be made without departing from the spirit and scope of the invention, as defined in the claims below. The present invention encompasses all combinations of various embodiments or aspects of the invention described herein. It is understood that any and all embodiments of the present invention may be taken in conjunction with any other embodiment to describe additional embodiments of the present invention. Furthermore, any elements of an embodiment may be combined with any and all other elements of any of the embodiments to describe additional embodiments.
The present application is a continuation of U.S. patent application Ser. No. 15/534,891, filed Jun. 9, 2017, which claims the priority benefits of International Patent Application No. PCT/US2015/067407, filed Dec. 22, 2015, which claims priority from U.S. patent application Ser. No. 62/234,335, filed on Sep. 29, 2015, and U.S. patent application Ser. No. 62/151,150, filed on Apr. 22, 2015, and U.S. patent application Ser. No. 62/115,689, filed on Feb. 13, 2015, and U.S. patent application Ser. No. 62/097,295, filed on Dec. 29, 2014, which are all hereby incorporated by reference herein in their entireties.
Number | Name | Date | Kind |
---|---|---|---|
4403604 | Wilkinson et al. | Sep 1983 | A |
4607618 | Angelchik | Aug 1986 | A |
5234454 | Bangs | Aug 1993 | A |
5306300 | Berry | Apr 1994 | A |
5366504 | Andersen et al. | Nov 1994 | A |
5507755 | Gresl et al. | Apr 1996 | A |
5662713 | Andersen et al. | Sep 1997 | A |
5741279 | Gordon et al. | Apr 1998 | A |
5820584 | Crabb | Oct 1998 | A |
6146416 | Andersen et al. | Nov 2000 | A |
6264700 | Kilcoyne et al. | Jul 2001 | B1 |
6280415 | Johnson | Aug 2001 | B1 |
6312437 | Kortenbach | Nov 2001 | B1 |
6355070 | Andersen et al. | Mar 2002 | B1 |
6398802 | Yee | Jun 2002 | B1 |
6432040 | Meah | Aug 2002 | B1 |
6447533 | Adams | Sep 2002 | B1 |
6468298 | Pelton | Oct 2002 | B1 |
6544291 | Taylor | Apr 2003 | B2 |
6558400 | Deem et al. | May 2003 | B2 |
6572627 | Gabbay | Jun 2003 | B2 |
6656194 | Gannoe et al. | Dec 2003 | B1 |
6675809 | Stack et al. | Jan 2004 | B2 |
6736828 | Adams et al. | May 2004 | B1 |
6740121 | Geitz | May 2004 | B2 |
6746460 | Gannoe et al. | Jun 2004 | B2 |
6755869 | Geitz | Jun 2004 | B2 |
6773440 | Gannoe et al. | Aug 2004 | B2 |
6800081 | Parodi | Oct 2004 | B2 |
6802868 | Silverman et al. | Oct 2004 | B2 |
6845776 | Stack et al. | Jan 2005 | B2 |
6916332 | Adams | Jul 2005 | B2 |
6960233 | Berg et al. | Nov 2005 | B1 |
6981978 | Gannoe | Jan 2006 | B2 |
6994095 | Burnett | Feb 2006 | B2 |
6994715 | Gannoe et al. | Feb 2006 | B2 |
7025791 | Levine et al. | Apr 2006 | B2 |
7033373 | de la Torre et al. | Apr 2006 | B2 |
7033384 | Gannoe et al. | Apr 2006 | B2 |
7037344 | Kagan et al. | May 2006 | B2 |
7044979 | Silverman et al. | May 2006 | B2 |
7066945 | Hashiba et al. | Jun 2006 | B2 |
7083629 | Weller et al. | Aug 2006 | B2 |
7083630 | DeVries et al. | Aug 2006 | B2 |
7087088 | Berg et al. | Aug 2006 | B2 |
7097650 | Weller et al. | Aug 2006 | B2 |
7097665 | Stack et al. | Aug 2006 | B2 |
7111627 | Stack et al. | Sep 2006 | B2 |
7146984 | Stack et al. | Dec 2006 | B2 |
7152607 | Stack et al. | Dec 2006 | B2 |
7211114 | Bessler et al. | May 2007 | B2 |
7220284 | Kagan et al. | May 2007 | B2 |
7232461 | Ramer | Jun 2007 | B2 |
7347875 | Levine et al. | Mar 2008 | B2 |
7431725 | Stack et al. | Oct 2008 | B2 |
7445010 | Kugler et al. | Nov 2008 | B2 |
7449024 | Stafford | Nov 2008 | B2 |
7682330 | Meade et al. | Mar 2010 | B2 |
7704264 | Ewers et al. | Apr 2010 | B2 |
7708752 | Durgin | May 2010 | B2 |
7753870 | Demarais et al. | Jul 2010 | B2 |
7771382 | Levine et al. | Aug 2010 | B2 |
7794447 | Dann et al. | Sep 2010 | B2 |
7815589 | Meade et al. | Oct 2010 | B2 |
7815591 | Levine et al. | Oct 2010 | B2 |
7846174 | Baker et al. | Dec 2010 | B2 |
7922650 | McWeeney et al. | Apr 2011 | B2 |
7976488 | Levine et al. | Jul 2011 | B2 |
7981163 | Meade et al. | Jul 2011 | B2 |
8029455 | Stack et al. | Oct 2011 | B2 |
8043355 | Shin et al. | Oct 2011 | B2 |
8100931 | Baker et al. | Jan 2012 | B2 |
8137301 | Levine et al. | Mar 2012 | B2 |
8162871 | Levine et al. | Apr 2012 | B2 |
8282598 | Belhe et al. | Oct 2012 | B2 |
8372087 | Baker et al. | Feb 2013 | B2 |
8447403 | Sharma et al. | May 2013 | B2 |
8506477 | Waller et al. | Aug 2013 | B2 |
8529431 | Baker et al. | Sep 2013 | B2 |
8556956 | Cully et al. | Oct 2013 | B2 |
8672831 | Baker et al. | Mar 2014 | B2 |
8721528 | Ho et al. | May 2014 | B2 |
8778011 | Ryan | Jul 2014 | B2 |
8784436 | Ho et al. | Jul 2014 | B2 |
8801599 | Baker et al. | Aug 2014 | B2 |
8894670 | Baker et al. | Nov 2014 | B2 |
9055998 | Baker | Jun 2015 | B2 |
9107742 | Cully et al. | Aug 2015 | B2 |
9198789 | Baker et al. | Dec 2015 | B2 |
9375338 | Baker et al. | Jun 2016 | B2 |
9414948 | Baker et al. | Aug 2016 | B2 |
9545326 | Baker et al. | Jan 2017 | B2 |
9549833 | McHugo | Jan 2017 | B2 |
9629733 | Roeder et al. | Apr 2017 | B2 |
20010020189 | Taylor | Sep 2001 | A1 |
20020032487 | Dua et al. | Mar 2002 | A1 |
20020091395 | Gabbay | Jul 2002 | A1 |
20030040804 | Stack et al. | Feb 2003 | A1 |
20030040808 | Stack et al. | Feb 2003 | A1 |
20030065359 | Weller et al. | Apr 2003 | A1 |
20030109935 | Geitz | Jun 2003 | A1 |
20030199989 | Stack et al. | Oct 2003 | A1 |
20030212450 | Schlick | Nov 2003 | A1 |
20040044357 | Gannoe et al. | Mar 2004 | A1 |
20040087976 | DeVries et al. | May 2004 | A1 |
20040092892 | Kagan et al. | May 2004 | A1 |
20040106987 | Palasis et al. | Jun 2004 | A1 |
20040116999 | Ledergerber | Jun 2004 | A1 |
20040117031 | Stack et al. | Jun 2004 | A1 |
20040138761 | Stack et al. | Jul 2004 | A1 |
20040143342 | Stack et al. | Jul 2004 | A1 |
20040148034 | Kagan et al. | Jul 2004 | A1 |
20040172141 | Stack et al. | Sep 2004 | A1 |
20040210111 | Okada | Oct 2004 | A1 |
20040220682 | Levine et al. | Nov 2004 | A1 |
20050004582 | Edoga et al. | Jan 2005 | A1 |
20050043683 | Ravo | Feb 2005 | A1 |
20050080395 | Levine et al. | Apr 2005 | A1 |
20050096728 | Ramer | May 2005 | A1 |
20050125020 | Meade et al. | Jun 2005 | A1 |
20050197715 | Kugler et al. | Sep 2005 | A1 |
20050228504 | Demarais | Oct 2005 | A1 |
20050245788 | Gerber | Nov 2005 | A1 |
20050245957 | Starkebaum et al. | Nov 2005 | A1 |
20050247320 | Stack et al. | Nov 2005 | A1 |
20050251165 | Vaughan et al. | Nov 2005 | A1 |
20050251176 | Swanstrom et al. | Nov 2005 | A1 |
20050283235 | Kugler et al. | Dec 2005 | A1 |
20060020277 | Gostout et al. | Jan 2006 | A1 |
20060036293 | Whitehurst et al. | Feb 2006 | A1 |
20060064120 | Levine et al. | Mar 2006 | A1 |
20060074473 | Gertner | Apr 2006 | A1 |
20060089571 | Gertner | Apr 2006 | A1 |
20060142844 | Lowe et al. | Jun 2006 | A1 |
20060149307 | Durgin | Jul 2006 | A1 |
20060155375 | Kagan et al. | Jul 2006 | A1 |
20060161139 | Levine et al. | Jul 2006 | A1 |
20060190019 | Gannoe et al. | Aug 2006 | A1 |
20060247721 | Maschino et al. | Nov 2006 | A1 |
20060253131 | Wolniewicz, III | Nov 2006 | A1 |
20060253142 | Bjerken | Nov 2006 | A1 |
20060253191 | Salahieh et al. | Nov 2006 | A1 |
20060264699 | Gertner | Nov 2006 | A1 |
20060265082 | Meade et al. | Nov 2006 | A1 |
20070005147 | Levine et al. | Jan 2007 | A1 |
20070010866 | Dann et al. | Jan 2007 | A1 |
20070010875 | Trout et al. | Jan 2007 | A1 |
20070088428 | Teichman | Apr 2007 | A1 |
20070112409 | Wu et al. | May 2007 | A1 |
20070123994 | Ortiz et al. | May 2007 | A1 |
20070166396 | Badylak et al. | Jul 2007 | A1 |
20070179590 | Lu et al. | Aug 2007 | A1 |
20070198035 | Threlkeld | Aug 2007 | A1 |
20070208429 | Leahy | Sep 2007 | A1 |
20070233221 | Raju | Oct 2007 | A1 |
20070260112 | Rahmani | Nov 2007 | A1 |
20070276432 | Stack et al. | Nov 2007 | A1 |
20070293716 | Baker et al. | Dec 2007 | A1 |
20080015523 | Baker | Jan 2008 | A1 |
20080015618 | Sonnenschein et al. | Jan 2008 | A1 |
20080015633 | Abbott et al. | Jan 2008 | A1 |
20080065122 | Stack et al. | Mar 2008 | A1 |
20080065136 | Young | Mar 2008 | A1 |
20080215076 | Baker | Sep 2008 | A1 |
20080312678 | Pasricha | Dec 2008 | A1 |
20090138071 | Cheng et al. | May 2009 | A1 |
20090177215 | Stack et al. | Jul 2009 | A1 |
20090187230 | Dilorenzo | Jul 2009 | A1 |
20090240340 | Levine et al. | Sep 2009 | A1 |
20090248171 | Levine et al. | Oct 2009 | A1 |
20090270818 | Duke | Oct 2009 | A1 |
20100010298 | Bakos et al. | Jan 2010 | A1 |
20100030017 | Baker et al. | Feb 2010 | A1 |
20100063518 | Baker et al. | Mar 2010 | A1 |
20100114124 | Kelleher et al. | May 2010 | A1 |
20100114130 | Meade et al. | May 2010 | A1 |
20100198237 | Baker et al. | Aug 2010 | A1 |
20100256775 | Belhe et al. | Oct 2010 | A1 |
20100280313 | Gasche et al. | Nov 2010 | A1 |
20110004146 | Priplata et al. | Jan 2011 | A1 |
20110009690 | Belhe et al. | Jan 2011 | A1 |
20110092879 | Baker et al. | Apr 2011 | A1 |
20110264234 | Baker et al. | Oct 2011 | A1 |
20120083871 | Ryan | Apr 2012 | A1 |
20120089168 | Baker et al. | Apr 2012 | A1 |
20120095497 | Babkes et al. | Apr 2012 | A1 |
20120191213 | Baker et al. | Jul 2012 | A1 |
20120191215 | Baker et al. | Jul 2012 | A1 |
20120203061 | Birk | Aug 2012 | A1 |
20120289991 | Baker | Nov 2012 | A1 |
20120310327 | McHugo | Dec 2012 | A1 |
20130123811 | Baker et al. | May 2013 | A1 |
20130296913 | Foote et al. | Nov 2013 | A1 |
20130324902 | Miller et al. | Dec 2013 | A1 |
20140018611 | Baker et al. | Jan 2014 | A1 |
20140114230 | Baker et al. | Apr 2014 | A1 |
20140121585 | Baker et al. | May 2014 | A1 |
20140277341 | Havel et al. | Sep 2014 | A1 |
20140309681 | Baker et al. | Oct 2014 | A1 |
20150025313 | Baker et al. | Jan 2015 | A1 |
20150039092 | Baker et al. | Feb 2015 | A1 |
20150182239 | Baker et al. | Jul 2015 | A1 |
20150265400 | Eidenschink | Sep 2015 | A1 |
20160038325 | Baker et al. | Feb 2016 | A1 |
20160151233 | Baker et al. | Jun 2016 | A1 |
20160228268 | Hingston et al. | Aug 2016 | A1 |
20160262867 | Baker et al. | Sep 2016 | A1 |
20160324671 | Baker et al. | Nov 2016 | A1 |
20170172723 | Foote et al. | Jun 2017 | A1 |
Number | Date | Country |
---|---|---|
0760696 | Aug 2001 | EP |
1808888 | Jul 2007 | EP |
2240215 | Jan 2014 | EP |
2660101 | Jun 1997 | JP |
2006-103873 | Apr 2006 | JP |
2007508053 | Apr 2007 | JP |
2011509758 | Mar 2011 | JP |
2045233 | Oct 1995 | RU |
94026119 | Aug 1996 | RU |
2386455 | Apr 2010 | RU |
WO 9322986 | Nov 1993 | WO |
WO 9412136 | Jun 1994 | WO |
WO 0135834 | May 2001 | WO |
WO 0185034 | Nov 2001 | WO |
WO 02060328 | Aug 2002 | WO |
WO 02094105 | Nov 2002 | WO |
WO 2004019826 | Mar 2004 | WO |
WO 2004064680 | Aug 2004 | WO |
WO 2004064685 | Aug 2004 | WO |
WO 2005037152 | Apr 2005 | WO |
WO 2006044640 | Apr 2006 | WO |
WO 2006078672 | Jul 2006 | WO |
WO 2007092390 | Aug 2007 | WO |
WO 2008100984 | Aug 2008 | WO |
WO 2008101048 | Aug 2008 | WO |
WO 2008101078 | Aug 2008 | WO |
WO 2009048398 | Apr 2009 | WO |
WO 2009091899 | Jul 2009 | WO |
2010117641 | Oct 2010 | WO |
WO 2011056608 | May 2011 | WO |
WO 2011063307 | May 2011 | WO |
WO 2011089601 | Jul 2011 | WO |
WO 2011097209 | Aug 2011 | WO |
WO 2011116025 | Sep 2011 | WO |
WO 2012044917 | Apr 2012 | WO |
2012136249 | Oct 2012 | WO |
WO 2012162114 | Nov 2012 | WO |
WO 2013090190 | Jun 2013 | WO |
WO 2013134227 | Sep 2013 | WO |
WO 2014141239 | Sep 2014 | WO |
WO 2015031077 | Mar 2015 | WO |
WO 2016109346 | Jul 2016 | WO |
Entry |
---|
International Search Report of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US12/38480, dated Jul. 30, 2012. |
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US12/38480, dated Nov. 29, 2013. |
“Obesity: Super-Sized Medical Device Market”, Start-Up, Mar. 2003, Technology Strategies (Long Article), pp. 1-10 and a cover page. |
Andrew S. Lowe, M.D. and Maria B. Sheridan, M.D., “Esphogeal Stenting”, Seminars in Interventional Radiology, vol. 21, No. 3, 2004, pp. 157-166. |
“Polyflex® Espohageal Stent”, Silicone Covered Stent, Boston Scientific, three pages (2003). |
Andrew F.R. Dixon, Johgn B. Dixon, and Paul E. O'Brien, “Laparoscopic Adjustable Gastric Banding Induces Prolonged Satiety: A Randomized Blind Crossover Study”, The Journal of Clinical Endocrinology & Metabolism , pp. 813-819, 2005. |
Roman, S. et al., “Intragastric balloon for ‘non-morbid’ obesity: a retrospective evaluation of tolerance and efficacy,” Obes. Surg., 2004, 14(4), 539-44, abstract, [on-line], [found Apr. 17, 2009, from Pubmed database]. |
Busetto, L. et al., “Preoperative weight loss by intragastric balloon in super-obese patients treated with laparoscopic gastric banding: a case-control study,” Obes Surg., 2004, 14(5), 671-6, abstract, [on-line], [found Apr. 17, 2009, from Pubmed database]. |
Summary of Official Action dated Oct. 29, 2009, from the Israel Patent Office in a patent application corresponding to the present application. |
Lowe, Andrew S., M.D. and Sheridan, Maria B., M.D., “Esophageal Stenting,” annotated by Israel Patent Office (2004). |
Abstract and claims of U.S. Pat. No. 6,960,233 annotated by the Israel Patent Office (Nov. 1, 2005). |
Schembre, Drew, “Advances in Esophageal Stenting: the Evolution of Fully Covered Stents for Malignant and Benign Disease,” Adv. Ther., Springer Healthcare, Apr. 1, 2010, pp. 1-13. |
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US08/53912, completed Aug. 19, 2009. |
International Preliminary Report on Patentability and Written Opinion of the International Searching Authority from corresponding Patent Cooperation Treaty (PCT) Patent Application No. PCT/US05/36991, completed Mar. 6, 2006. |
S. Fukudo, T. Nomura, M. Hongo, “Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowl syndrome”, Jan. 19, 1998. |
D.G. Maxton, D.F. Martin, P.J. Whorwell, M. Godfrey. “Abdominal distension in female patients with irritable bowel syndrome: exploration of possible mechanisms”, Aug. 3, 1990. |
Number | Date | Country | |
---|---|---|---|
20180250119 A1 | Sep 2018 | US |
Number | Date | Country | |
---|---|---|---|
62234355 | Sep 2015 | US | |
62151150 | Apr 2015 | US | |
62115689 | Feb 2015 | US | |
62097295 | Dec 2014 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15534891 | US | |
Child | 15974054 | US |